A Phase II Study of Pioglitazone for Patients With Cancer of the Pancreas
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs Pioglitazone (Primary)
- Indications Adenocarcinoma; Insulin resistance; Pancreatic cancer
- Focus Pharmacodynamics
- 09 May 2018 Status changed from recruiting to completed.
- 06 Jun 2017 Primary endpoint (Adiponectin levels) has been met as per the results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2017 Results (n=14) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology